ImportantArrangements for strategic, technical, manufacturing, or marketing tie up
Lupin's subsidiary VISUfarma inked an exclusive deal with Visus Therapeutics to commercialize YUVEZZI™ for presbyopia in Europe.
Lupin LimitedLUPIN · Filed with the exchange
This strengthens Lupin’s ophthalmology portfolio and expands its specialty business, targeting long-term growth.
The deal involves up to €7.5 Cr plus royalties.
No comments yet. Be the first.